Welcome to our dedicated page for SVAP news (Ticker: SVAP), a resource for investors and traders seeking the latest updates and insights on SVAP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SVAP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SVAP's position in the market.
Standard Vape Corporation (OTC PINK:SVAP) has published its unaudited financial statements for the quarter and half-year ended June 30, 2021, due to a recent change of control. The company is currently waiting for new filer codes from OTC Markets to publish its financials in the customary format. The financial statements for April 1, 2021, to June 30, 2021, and for January 1, 2021, to June 30, 2021, are available on its website. The corporation plans to upload these financials to OTC Markets once the necessary codes are provided.
Standard Vape Corporation (SVAP) has completed a reverse takeover with Fast Finance Holding AG, marking a significant shift in control and business focus towards financial technology. The effective date of this change was May 10, 2021. SVAP acquired two subsidiaries, FF24 Merchant Services GmbH and FF24 Ventures GmbH, and issued 100,000 shares of Class D Convertible Voting Preferred Stock to FF24. Management changes ensued, with new executives from FF24 leading the company. The transaction involved returning Nano Vape Corporation to its shareholders and resulted in a new outstanding common share count of 138,256,970.
Standard Vape (SVAP) has announced the initiation of animal studies for its NanoNOx™ nitric oxide dry powder inhaler as a potential treatment for COVID-19. The studies, conducted in collaboration with Bioneeds India Private Limited, aim to assess the toxicity of NanoNOx™ in rats and rabbits. Positive results may lead to a preIND filing with the FDA for clinical trials. The technology claims to offer a portable and efficient outpatient treatment option, eliminating the need for gas tanks. Preliminary agreements for clinical studies have been reached with researchers at UC Davis and Montefiore Medical Center.
